[go: up one dir, main page]

FI942913L - Isatinderivat, förfarande för deras framställning och farmaceutiska kompositioner innehållande dem - Google Patents

Isatinderivat, förfarande för deras framställning och farmaceutiska kompositioner innehållande dem Download PDF

Info

Publication number
FI942913L
FI942913L FI942913A FI942913A FI942913L FI 942913 L FI942913 L FI 942913L FI 942913 A FI942913 A FI 942913A FI 942913 A FI942913 A FI 942913A FI 942913 L FI942913 L FI 942913L
Authority
FI
Finland
Prior art keywords
preparation
methods
pharmaceutical compositions
compositions containing
isatin derivatives
Prior art date
Application number
FI942913A
Other languages
English (en)
Finnish (fi)
Other versions
FI942913A0 (sv
Inventor
Bernard Robin Boar
Alan John Cross
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Publication of FI942913A0 publication Critical patent/FI942913A0/sv
Publication of FI942913L publication Critical patent/FI942913L/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/38—Oxygen atoms in positions 2 and 3, e.g. isatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FI942913A 1991-12-18 1994-06-17 Isatinderivat, förfarande för deras framställning och farmaceutiska kompositioner innehållande dem FI942913L (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9103752A SE9103752D0 (sv) 1991-12-18 1991-12-18 New compounds
PCT/SE1992/000873 WO1993012085A1 (en) 1991-12-18 1992-12-16 Isatin derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same

Publications (2)

Publication Number Publication Date
FI942913A0 FI942913A0 (sv) 1994-06-17
FI942913L true FI942913L (sv) 1994-08-17

Family

ID=20384648

Family Applications (1)

Application Number Title Priority Date Filing Date
FI942913A FI942913L (sv) 1991-12-18 1994-06-17 Isatinderivat, förfarande för deras framställning och farmaceutiska kompositioner innehållande dem

Country Status (23)

Country Link
US (1) US5585378A (sv)
EP (1) EP0624156A1 (sv)
JP (1) JPH07502272A (sv)
CN (1) CN1034939C (sv)
AP (1) AP389A (sv)
AU (1) AU675055B2 (sv)
BG (1) BG98815A (sv)
CA (1) CA2124826A1 (sv)
CZ (1) CZ146694A3 (sv)
EE (1) EE9400428A (sv)
FI (1) FI942913L (sv)
HU (1) HUT69704A (sv)
IL (1) IL104107A0 (sv)
IS (1) IS3958A (sv)
MX (1) MX9207382A (sv)
NO (1) NO942316D0 (sv)
PL (1) PL170736B1 (sv)
SE (1) SE9103752D0 (sv)
SI (1) SI9200405A (sv)
SK (1) SK278321B6 (sv)
TN (1) TNSN92114A1 (sv)
WO (1) WO1993012085A1 (sv)
ZA (1) ZA929700B (sv)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620973A (en) * 1993-11-30 1997-04-15 Takeda Chemical Industries, Ltd. Tetracyclic condensed heterocyclic compounds and their use
SE9504267D0 (sv) * 1995-11-29 1995-11-29 Astra Ab New therapeutic use
GB2308362A (en) 1995-12-19 1997-06-25 Lilly Industries Ltd Pharmaceutical indole derivatives
WO1998007431A1 (en) * 1996-08-22 1998-02-26 New York University Cholinesterase inhibitors for treatment of parkinson's disease
WO1998008816A1 (fr) * 1996-08-26 1998-03-05 Meiji Seika Kaisha, Ltd. Derives d'indoxyle et psychotropes
BR9908510A (pt) * 1998-03-06 2000-11-21 Astrazeneca Ab Uso de um composto, composto, processo para a preparação de um composto, composição farmacêutica, e, processo de tratar um paciente que sofre de, ou em risco de, uma doença micobacteriana
GB9810886D0 (en) * 1998-05-13 1998-07-22 Lilly Industries Ltd Pharmaceutical compounds
GB9820489D0 (en) * 1998-09-22 1998-11-11 Steiger Malcolm J Compounds for improved treatment of parkinson's disease
KR100648869B1 (ko) 1998-09-30 2007-02-28 다케다 야쿠힌 고교 가부시키가이샤 방광 배출력 개선제
US6319912B1 (en) 1999-05-04 2001-11-20 American Home Products Corporation Cyclic regimens using 2,1-benzisothiazoline 2,2-dioxides
US6423699B1 (en) 1999-05-04 2002-07-23 American Home Products Corporation Combination therapies using benzimidazolones
US6509334B1 (en) 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6407101B1 (en) 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6339098B1 (en) 1999-05-04 2002-01-15 American Home Products Corporation 2,1-benzisothiazoline 2,2-dioxides
US6391907B1 (en) 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6369056B1 (en) 1999-05-04 2002-04-09 American Home Products Corporation Cyclic urea and cyclic amide derivatives
US6380235B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Benzimidazolones and analogues
US6417214B1 (en) 1999-05-04 2002-07-09 Wyeth 3,3-substituted indoline derivatives
US6380178B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Cyclic regimens using cyclocarbamate and cyclic amide derivatives
US6399593B1 (en) 1999-05-04 2002-06-04 Wyeth Cyclic regimens using cyclic urea and cyclic amide derivatives
US6462032B1 (en) 1999-05-04 2002-10-08 Wyeth Cyclic regimens utilizing indoline derivatives
US6444668B1 (en) 1999-05-04 2002-09-03 Wyeth Combination regimens using progesterone receptor modulators
US6355648B1 (en) 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
US6329416B1 (en) 1999-05-04 2001-12-11 American Home Products Corporation Combination regimens using 3,3-substituted indoline derivatives
US6358947B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Tetracyclic progesterone receptor modulator compounds and methods
US6306851B1 (en) 1999-05-04 2001-10-23 American Home Products Corporation Cyclocarbamate and cyclic amide derivatives
US6358948B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
US6498154B1 (en) 1999-05-04 2002-12-24 Wyeth Cyclic regimens using quinazolinone and benzoxazine derivatives
EP1311272B1 (en) * 2000-03-03 2006-11-22 Eisai Co., Ltd. Novel methods using cholinesterase inhibitors
US20030153598A1 (en) * 2000-07-25 2003-08-14 Raymond Pratt Methods for treating Parkinson's disease with cholinesterase inhibitors
UA73119C2 (en) 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
CN1317276C (zh) * 2000-09-29 2007-05-23 中国科学院上海药物研究所 一类吲哚基哌啶类化合物及其制备方法和用途
WO2002070478A1 (en) 2001-03-06 2002-09-12 Astrazeneca Ab Indolone derivatives having vascular-damaging activity
US6770638B2 (en) 2001-04-20 2004-08-03 Spectrum Pharmaceuticals, Inc. Tetrahydroindolone and purine derivatives linked to arylpiperazines
EP1764134B1 (en) * 2001-07-30 2009-01-28 Spectrum Pharmaceuticals, Inc. Purine derivatives linked to arylpiperazines
DE60231070D1 (de) * 2001-07-30 2009-03-19 Spectrum Pharmaceuticals Inc Arylpiperazin gebundene Purinderivate
CA2580730C (en) * 2003-09-25 2015-01-13 Cenomed, Inc. Tetrahydroindolone derivatives for treatment of neurological conditions
US20050107439A1 (en) * 2003-11-10 2005-05-19 Helton David R. Composition and method for treating emesis
GT200500185A (es) * 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
MY150958A (en) * 2005-06-16 2014-03-31 Astrazeneca Ab Compounds for the treatment of multi-drug resistant bacterial infections
US9238150B2 (en) 2005-07-22 2016-01-19 The Board Of Trustees Of The Leland Stanford Junior University Optical tissue interface method and apparatus for stimulating cells
US9274099B2 (en) 2005-07-22 2016-03-01 The Board Of Trustees Of The Leland Stanford Junior University Screening test drugs to identify their effects on cell membrane voltage-gated ion channel
US20090093403A1 (en) 2007-03-01 2009-04-09 Feng Zhang Systems, methods and compositions for optical stimulation of target cells
US8926959B2 (en) 2005-07-22 2015-01-06 The Board Of Trustees Of The Leland Stanford Junior University System for optical stimulation of target cells
EP1919497B1 (en) 2005-07-22 2020-02-12 The Board of Trustees of the Leland Stanford Junior University Light-activated cation channel and uses thereof
US10052497B2 (en) 2005-07-22 2018-08-21 The Board Of Trustees Of The Leland Stanford Junior University System for optical stimulation of target cells
US8398692B2 (en) 2007-01-10 2013-03-19 The Board Of Trustees Of The Leland Stanford Junior University System for optical stimulation of target cells
WO2008101128A1 (en) 2007-02-14 2008-08-21 The Board Of Trustees Of The Leland Stanford Junior University System, method and applications involving identification of biological circuits such as neurological characteristics
US10035027B2 (en) 2007-10-31 2018-07-31 The Board Of Trustees Of The Leland Stanford Junior University Device and method for ultrasonic neuromodulation via stereotactic frame based technique
US10434327B2 (en) 2007-10-31 2019-10-08 The Board Of Trustees Of The Leland Stanford Junior University Implantable optical stimulators
EP2219648A4 (en) * 2007-11-09 2010-11-03 Cenomed Biosciences Llc TREATMENT OF POSTRAUMATIC STRESS WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS
US20090264443A1 (en) * 2008-04-18 2009-10-22 David Helton Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds
MX2010011657A (es) 2008-04-23 2011-01-21 Univ Leland Stanford Junior Sistemas, metodos y composiciones para la estimulacion optica de celulas objetivo.
ES2532235T3 (es) 2008-05-29 2015-03-25 The Board Of Trustees Of The Leland Stanford Junior University Línea celular, sistema y procedimiento para el control óptico de mensajeros secundarios
AU2009260027B2 (en) 2008-06-17 2015-12-03 The Board Of Trustees Of The Leland Stanford Junior University Apparatus and methods for controlling cellular development
WO2010006049A1 (en) 2008-07-08 2010-01-14 The Board Of Trustees Of The Leland Stanford Junior University Materials and approaches for optical stimulation of the peripheral nervous system
NZ602416A (en) 2008-11-14 2014-08-29 Univ Leland Stanford Junior Optically-based stimulation of target cells and modifications thereto
WO2010090680A1 (en) * 2008-12-15 2010-08-12 Wyeth Llc Substituted oxindole cb2 agonists
WO2011116238A2 (en) 2010-03-17 2011-09-22 The Board Of Trustees Of The Leland Stanford Junior University. Light-sensitive ion-passing molecules
US8598156B2 (en) 2010-03-25 2013-12-03 Glaxosmithkline Llc Chemical compounds
CN101863823B (zh) * 2010-06-03 2012-02-08 山东大学 吲哚二酮类化合物及其扩环衍生物、制备方法及应用
US10086012B2 (en) 2010-11-05 2018-10-02 The Board Of Trustees Of The Leland Stanford Junior University Control and characterization of memory function
AU2011323199B2 (en) 2010-11-05 2016-01-28 The Board Of Trustees Of The Leland Stanford Junior University Stabilized step function opsin proteins and methods of using the same
WO2012061679A2 (en) 2010-11-05 2012-05-10 The Board Of Trustees Of The Leland Stanford Junior University Light-activated chimeric opsins and methods of using the same
CN103476456B (zh) * 2010-11-05 2017-10-03 斯坦福大学托管董事会 奖赏相关行为的光遗传学控制
EP2635341B1 (en) 2010-11-05 2018-08-08 The Board of Trustees of the Leland Stanford Junior University Upconversion of light for use in optogenetic methods
WO2012061690A2 (en) 2010-11-05 2012-05-10 The Board Of Trustees Of The Leland Stanford Junior University Optically-controlled cns dysfunction
US8696722B2 (en) 2010-11-22 2014-04-15 The Board Of Trustees Of The Leland Stanford Junior University Optogenetic magnetic resonance imaging
CN104093833B (zh) 2011-12-16 2017-11-07 斯坦福大学托管董事会 视蛋白多肽及其使用方法
ES2628006T3 (es) 2012-02-21 2017-08-01 Circuit Therapeutics, Inc. Composiciones para el tratamiento de trastornos neurogénicos del suelo pélvico
CN103006642B (zh) * 2013-01-04 2014-10-22 中国药科大学 一类炔亚甲基吲哚-2-酮类衍生物的用途
US9636380B2 (en) 2013-03-15 2017-05-02 The Board Of Trustees Of The Leland Stanford Junior University Optogenetic control of inputs to the ventral tegmental area
EP2968997B1 (en) 2013-03-15 2019-06-26 The Board of Trustees of the Leland Stanford Junior University Optogenetic control of behavioral state
AU2014260101B2 (en) 2013-04-29 2018-07-26 Humboldt-Universitat Zu Berlin Devices, systems and methods for optogenetic modulation of action potentials in target cells
CN103242332B (zh) * 2013-05-13 2015-11-04 江西科技师范大学 1-n酰基取代吲哚酮衍生物
CN104530065A (zh) * 2013-05-13 2015-04-22 江西科技师范大学 1-n酰基取代吲哚酮衍生物的应用
US10307609B2 (en) 2013-08-14 2019-06-04 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for controlling pain
CN103420941B (zh) * 2013-08-26 2015-09-23 浙江大学 2-甲氧基苯基-二甲胺基甲酸酯衍生物及制备和用途
WO2016209654A1 (en) 2015-06-22 2016-12-29 The Board Of Trustees Of The Leland Stanford Junior University Methods and devices for imaging and/or optogenetic control of light-responsive neurons
US11294165B2 (en) 2017-03-30 2022-04-05 The Board Of Trustees Of The Leland Stanford Junior University Modular, electro-optical device for increasing the imaging field of view using time-sequential capture
CN117624015B (zh) * 2023-12-06 2024-08-16 广东医科大学 一种取代靛红-褪黑激素衍生物及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3573310A (en) * 1967-09-28 1971-03-30 Miles Lab 1-substituted derivatives of 2-indolinone
US3635976A (en) * 1967-12-20 1972-01-18 Pennwalt Corp 1 - heterocyclic alkyl-1 2 3 4-tetrahydroquinazolinones and analgesic intermediates thereof
DE2123923A1 (de) * 1971-05-14 1972-11-23 Boehringer Mannheim Gmbh, 6800 Mannheim 4-eckige Klammer auf omega- (Flavon-7yl-oxy) -alkyl eckige Klammer zu -pigerazin-Derivate und Verfahren zu ihrer Herstellung
GR65270B (en) * 1978-10-10 1980-07-31 Fujisawa Pharmaceutical Co Isatin derivatives and processes for the preparation thereof
US4692448A (en) * 1984-11-20 1987-09-08 Boehringer Ingelheim Pharmaceuticals, Inc. Bis(arylpiperazinyl)sulfur compounds
JPS62294654A (ja) * 1986-06-13 1987-12-22 Kissei Pharmaceut Co Ltd イサチン誘導体
FI95572C (sv) * 1987-06-22 1996-02-26 Eisai Co Ltd Förfarande för framställning av ett som läkemedel användbart piperidinderivat eller dess farmaceutiska salt
FR2651230B1 (fr) * 1989-08-25 1992-03-13 Synthese Rech Derives de la 5-amino-1,2,3,4 tetrahydro-acridine et applications comme medicaments.
RU2124511C1 (ru) * 1993-05-14 1999-01-10 Фармасьютикал Ко., Лтд Производные пиперазина
SE9302080D0 (sv) * 1993-06-16 1993-06-16 Ab Astra New compounds

Also Published As

Publication number Publication date
EP0624156A1 (en) 1994-11-17
NO942316L (no) 1994-06-17
SK73494A3 (en) 1995-03-08
HUT69704A (en) 1995-09-28
TNSN92114A1 (fr) 1993-06-08
CN1079464A (zh) 1993-12-15
JPH07502272A (ja) 1995-03-09
CN1034939C (zh) 1997-05-21
NO942316D0 (no) 1994-06-17
SE9103752D0 (sv) 1991-12-18
AU675055B2 (en) 1997-01-23
ZA929700B (en) 1993-08-10
US5585378A (en) 1996-12-17
FI942913A0 (sv) 1994-06-17
BG98815A (bg) 1995-05-31
PL170736B1 (pl) 1997-01-31
MX9207382A (es) 1993-07-01
AP9200464A0 (en) 1993-01-31
SI9200405A (en) 1993-06-30
AP389A (en) 1995-08-02
SK278321B6 (en) 1996-10-02
EE9400428A (et) 1996-04-15
IL104107A0 (en) 1993-05-13
WO1993012085A1 (en) 1993-06-24
IS3958A (is) 1993-06-19
HU9401844D0 (en) 1994-09-28
CZ146694A3 (en) 1995-06-14
CA2124826A1 (en) 1993-06-24
AU3175993A (en) 1993-07-19

Similar Documents

Publication Publication Date Title
FI942913A0 (sv) Isatinderivat, förfarande för deras framställning och farmaceutiska kompositioner innehållande dem
EE03177B1 (et) Heterobitsüklilised ühendid, nende saamismeetod ja nimetatud ühendeid sisaldavad farmatseutilised kompositsioonid
FI943571A (sv) 1-bensensulfonyl-1,3-dihydro-2H-bensimidazol-2-onderivat, deras framställning och farmaceutiska kompositioner innehållande desamma
EE9500064A (et) Asendatud 1H-imidasoolid, nende valmistamismeetodid ja farmatseutilised kompositsioonid
IL96385A0 (en) Indole derivatives,their preparation and pharmaceutical compositions containing them
IL105412A0 (en) Indole derivatives,their preparation and pharmaceutical compositions containing them
IL111314A0 (en) Indole derivatives, their preparation and pharmaceutical compositions containing them
FI941987L (sv) Nya aminosyraderivat, förfaranden för deras frmaställning samt sammansättningar innehållande dessa föreningar
NZ237041A (en) Substituted 1h-indole derivatives, preparation, pharmaceutical compositions and intermediates thereof
ZA923513B (en) New thiopyranopyrrole derivatives,their preparation and pharmaceutical compositions containing them
IL86877A0 (en) Indole derivatives,their preparation and pharmaceutical compositions containing them
IL109234A0 (en) Indole derivatives, their preparation and pharmaceutical compositions containing them
IL117104A (en) Tetrahydrocarbazole derivatives, process for their preparation and pharmaceutical compositions containing them
FI953898L (sv) Glycinamidderivat, förfarande för framställning av dessa och läkemedel innehållande dessa
FI954304L (sv) Nya bensopyranderivat, förfarande för deras framställning och farmaceutiska kompositioner, som innehåller dessa föreningar
IL108859A0 (en) Indole derivatives, their preparation and pharmaceutical compositions containing them
IL101042A0 (en) 3-piperidinyl-methylcarboxylate substituted indoles,their preparation and pharmaceutical compositions containing them
IL111294A0 (en) Indole derivatives, their preparation and pharmaceutical compositions containing them
IL110980A0 (en) Indole derivatives, their preparation and pharmaceutical compositions containing them
EE9800426A (et) Asendatud 2,4-tiasolidiindiooni derivaadid, nende valmistamismeetodid ja neid sisaldavad farmatseutilised kompositsioonid
FI943688L (sv) Nya 11-bensaldoxim-17beta-metoxi-17alfa-metoximetyl-estradienderivat, förfaranden för framställning av desamma och läkemedel innehållande dessa föreningar
IL112097A0 (en) Indoline derivatives, their preparation and pharmaceutical compositions containing them
FI951789L (sv) Nya taxanderivat, deras framställning och dessa innehållande farmaceutiska föreningar
EE9900112A (et) 2-tsüanoiminoimidasooli derivaadid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid
FI943645L (sv) Nya backatin-III och 10-deacetylbackatin-III-derivat, framställning av dem och dessa innehållande farmaceutiska kompositioner

Legal Events

Date Code Title Description
FD Application lapsed